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Interleukin-18 (IL-18) is a critical cytokine in inflammation and adaptive immune responses. The IL-18 binding proteins (IL-18BP) are a
family of proteins that bind to, and inhibit the activity of, IL-18. Using point mutagenesis, we analyzed the ectromelia virus IL-18BP to
identify residues involved in binding. Because p13 can bind both human and murine IL-18, and because it is highly homologous to the
variola virus IL-18BP, we set out to identify residues that may be involved in species specificity. Several of the mutations resulted in complete
abrogation of binding affinity. Three (F49A, E77A, and E69A) significantly affected binding with both species of IL-18, but not to the same
extent. Mutant H70A showed reduced affinity for human IL-18 while binding to murine IL-18 was not affected. This study demonstrated that
interaction of IL-18 with p13 was similar to other IL-18BPs, however, novel species-specific interactions were identified.
D 2004 Elsevier Inc. All rights reserved.Keywords: Orthopoxvirus; Interleukin-18; Interleukin-18 binding protein; Mutagenesis; Species specificity; Immune evasionIntroduction
Poxviruses are a family of large dsDNA viruses that
encode approximately 200 genes. With the eradication of
smallpox, molluscum contagiosum (MOCV) is the only
poxvirus limited to replication in a human host. MOCV
causes small, benign skin lesion in children or adults, and
only causes more extensive disease in the absence of a
functioning immune response, such as in AIDS (Buller and
Palumbo, 1991). Smallpox, a frequently lethal disease, is
caused by variola virus (VARV), an orthopoxvirus which
now officially exists only two secure repositories. Ortho-
poxviruses form a group of related viruses including vac-
cinia virus (VACV); the vaccine virus used for smallpox
eradication; monkeypox (MPXV), which can infect humans
and cause a smallpox-like disease; cowpox (CPXV), actu-
ally a rodent pathogen, and ectromelia virus (ECTV), a
pathogen of the mouse. The genomes of poxviruses are
organized similarly, with proteins essential for replication0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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response modifiers, which aid in immune evasion (Chen et
al., 2000). Many of these genes were likely picked up from
the host by a process of horizontal gene transfer, and thus
show significant homology to host genes.
A key strategy of poxvirus immune evasion is inhibition
of chemokine or cytokine activity through the expression of
soluble binding proteins that act as decoy receptors. Among
these, the interferon-g binding protein (IFN-gBP) and tumor
necrosis factor-a binding proteins are soluble cellular re-
ceptor homologs lacking the transmembrane domain
(Alcami and Smith, 1995; Alcami et al., 1999; Takahashi
et al., 2002; Upton et al., 1992), although others such as the
chemokine binding proteins are unique viral proteins
(Alcami, 2003; Alcami et al., 1998; Smith et al., 1997).
The poxvirus interleukin-18 binding proteins (IL-18BP) are
homologs of a cellular protein but lack significant sequence
similarity to the IL-18 receptor (Novick et al., 1999).
IL-18 plays a central role in inflammation and develop-
ment of the adaptive immune response. Initially described as
a potent inducer of IFN-g, IL-18 also induces other pro-
inflammatory cytokines and chemokines (Okamura et al.,
1995; Puren et al., 1998), actives NK-cell activity (Lauwerys
et al., 1999), and helps drive development of type-1 T-cells
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IL-18 is an important mediator in the host response to many
viral and bacterial infections. Indeed, viral infection induces
IL-18 release from macrophages (Pirhonen et al., 1999), and
treatment of mice with exogenous IL-18 confers protection in
mouse models of herpes simplex virus (Fujioka et al., 1999)
and VACV infections (Tanaka-Kataoka et al., 1999). The
protective effect is likely the result of a combination of IFN-
g-, NK-cell-, and T-cell-mediated events (Gherardi et al.,
2003; Reading and Smith, 2003). IL-18 is also implicated in
the damaging immune response of autoimmune diseases such
as Crohn’s disease and rheumatoid arthritis (Gracie et al.,
1999; Kanai et al., 2000; Pizarro et al., 1999; Yamamura et al.,
2001). In addition, human IL-18BP may be an important
regulator of IL-18 activity and may be a useful strategy for
therapy of certain autoimmune diseases.
IL-18 binding proteins (IL-18BP) were first identified in
humans and mice as proteins likely involved in an IL-18
regulatory mechanism (Aizawa et al., 1999; Novick et al.,
1999). IL-18BP expression is induced by IFN-g, indicating
that feedback regulation exists to control IL-18 activity
(Muhl et al., 2000). IL-18 and the IL-18BPs are expressed
primarily in immune tissues such as the spleen, but also in
nonimmune cells including keratinocytes. IL-18BPs have
been identified in ECTV, CPXV, VACV, MOCV, and
uncharacterized homologs exist in other poxviruses (Born
et al., 2000; Smith et al., 2000; Xiang and Moss, 1999a,
1999b). In infected animals, viral IL-18BPs have been
shown to suppress IL-18-mediated activities, including
IFN-g expression, NK-cell, and T-cell activity (Born et al.,
2000; Reading and Smith, 2003; Symons et al., 2002).
Mammalian and viral IL-18BPs are highly homologous
but differ significantly in sequence from the IL-18 receptor.
Modeling of the huIL-18BP/IL-18 complex identified spe-
cific residues which may be involved in binding (Kim et al.,Fig. 1. Multiple sequence alignment of p13, D7L (variola virus), C12L (vaccinia v
18BP, and IL-1R. Sequences were aligned using ClustalW and adjusted manual
medium gray boxes surround residues that are highly conserved, and light gray bo
sequences. Circles indicate residues in p13 selected for mutagenesis. Below the a
structure of IL-1R. Sequences were obtained from GenBank (accession numbers: p
MC54L: NC_001731; huIL-18BP: BAA76374; IL-1R: NM_000877).2000). Subsequent mutagenesis studies of huIL-18BP and
MOCV IL-18BP supported this model and demonstrated
conservation of functional epitopes in mammalian and viral
proteins (Xiang and Moss, 2001a, 2001b). In this study, we
extend analysis of IL-18–IL-18BP interactions to an ortho-
poxvirus IL-18BP (p13) whose natural ligand species is
mouse.
Human and mouse IL-18 are 85% homologous and the
cellular receptors bind in a species-specific manner. The IL-
18 binding proteins, however, have been shown to bind both
human and mouse IL-18, albeit with differing affinities. In
this study, we analyzed the interaction of IL-18 with p13
point mutants and demonstrate that functional epitopes in
huIL-18BP and MC54L are also present in p13. Further-
more, we show that there are significant differences between
hu and muIL-18 binding and identify novel residues in-
volved in species specificity.Results
Selection of mutants
Alignment of the members of the IL-18BP family reveals
regions and residues of high conservation (Fig. 1). Muta-
genic studies of huIL-18BP and MC54L have identified
many residues that play a role in interaction with their
human ligands (Xiang and Moss, 2001a, 2001b). MC54L
is the most divergent member of the family; however,
residues important in binding correspond to residues iden-
tified in huIL-18BP, indicating conservation of functional
epitopes. Furthermore, many IL-18BPs are capable of
binding IL-18 of other species, but the unique structural
elements that permit cross-species binding are not known.
To analyze the interaction of p13 with mu and huIL-18,irus), C8L (cowpox virus), MC54L (molluscum contagiosum virus), huIL-
ly. Dark gray boxes surround residues that are identical in all sequences,
xes surround residues that are identical in three or similar in three or more
lignment, arrows indicate the position and name of h-strands in the crystal
13: NP_671531; D7L: AAA60752; C12L: AAO89292; C8L: CAD90595.1;
Fig. 3. Cysteine mutants show abnormal secretion from cells. CV-1/EBNA-1
cells were transfected with the indicated mutants or wild-type p13, and
incubated for 48 h. Supernatants were collected and cells were lysed, and
analyzed by 12% SDS-PAGE followed by Western blot using anti-p13
antiserum. The bands were detected by chemiluminescence. The bands were
quantified by spot densitometry and the percentage in the secreted and
cellular fractions are reported to the right of the blots.
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conserved in the IL-18BP family or shown to be important
in previous studies on MC54L or huIL-18BP. In addition,
p13 contains four cysteines, which may be involved in the
formation of disulfide bonds essential for protein structure,
and were individually mutated to alanine. Compared to the
sequence of the mammalian IL-18BPs and MC54L, p13 and
the other orthopoxvirus IL-18BPs have an insertion of seven
residues (K60–K66), which may form an extended h-loop
structure. This insertion is also present in the IL-1R and is
located on the ligand interacting surface. Five charged
residues in this region unique to the orthopoxvirus IL-
18BPs were selected for mutagenesis.
Mutagenesis, expression, and purification
Mutants were constructed by converting specific codons
to alanine (gca) using mutagenic primers for site-directed
mutagenesis. Each sequence was verified on both strands.
The proteins were expressed from pDC409 in CV-1/EBNA-
1 cells as a secreted C-terminal fusion protein with a
fragment of human IgG1 Fc. Expression and secretion was
assessed by Western blot using rabbit anti-p13 antiserum or
antihuman IgG (not shown). Recombinant proteins were
purified from culture media by protein-G affinity chroma-
tography using FPLC. Bound protein was eluted with citrate
(pH 3) and peak fractions identified by UV-absorbance and
silver-stained PAGE were pooled and dialyzed into PBS.
Purity of each mutant was assessed by silver staining (Fig.
2) and was found to be greater than 95%.
All point mutants were expressed and secreted normally,
except the four cysteine mutants (Fig. 3). The individual
Cys mutants were not secreted, or were secreted at levels far
below wild type, suggesting these mutations may have
introduced significant conformational abnormalities. Fur-
thermore, repeated attempts to purify the Cys mutants from
cell extracts, or large volumes of accumulated supernatants,Fig. 2. Expression and purification of wild type and mutant proteins. Proteins w
protein in the culture media over 1- or 2-week incubations. Fc-fusion protei
chromatography. Bound protein was eluted in pH 3 citrate, and peak fractions wer
SDS-PAGE followed by silver stain.yielded only small amounts of protein, which precipitated
out of solution. Sufficient protein was recovered for only a
few tests for IL-18 binding by surface plasmon resonance
(SPR), and no protein–protein interaction was detected
(data not shown).
IL-18 binding by p13 mutants
The binding affinity of wild type and mutant proteins
was tested by SPR using a CM5 sensor chip with immobi-ere expressed by transfecting CV-1/EBNA-1 cells and collecting secreted
ns were purified from culture media by FPLC using protein-G affinity
e pooled and dialyzed into PBS. The purified protein was analyzed by 12%
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Fig. 5. Summary of kinetics and affinity of IL-18 binding by p13 mutants determined by SPR. Purified mutants and wild-type protein were captured using
antihuman IgG antibody immobilized on a BIAcore chip. Human or murine IL-18 was then injected at varying concentrations, and the sensograms were
analyzed by fitting to a 1:1 binding model to determine the dissociation rate (kd), association rate (ka), and affinity. The ka and kd of the mutants are plotted
along the y- and x-axes, respectively, and the affinity is plotted along the diagonal (a change in affinity is seen as a change in position along a different diagonal,
although points lying on the same diagonal have identical affinity but may differ in association and dissociation rates). Mutants are labeled with the specific
residue altered. Wild-type p13 binding muIL-18 is indicated by a black diamond and binding to huIL-18 by a black circle. Mutant interactions with muIL-18
are represented by gray squares and interactions with huIL-18 by open squares. Each mutant was tested by SPR at least three times. For the purposes of clarity,
error bars are not shown.
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or huIL-18 was injected at varying concentrations over the
reference cell containing only antibody and sample flow
cells with captured binding protein for 3 min, then allowed
to dissociate for 10 min. Bulk shift and noise from the
BIAcore hardware were eliminated by subtracting the ref-
erence cell signal and a buffer blank injection. The senso-
grams were globally fitted using a 1:1 binding model and
the kinetic values of the mutant and wild-type protein were
determined (Fig. 4). Wild-type p13 demonstrated higher
affinity for muIL-18 than huIL-18 due to a higher associ-
ation rate. All mutants that demonstrated IL-18 binding,
including those that decrease affinity, maintained a higher
association rate with muIL-18. Furthermore, mutations that
reduced affinity but did not eliminate binding did so via an
increase in the dissociation rate (Fig. 5). The exception is
E69A, which also had a reduction in the association rate
with huIL-18, but not muIL-18. F49A, E69A, and E77A
showed a difference from wild type in affinity for both
human and mouse IL-18 due to an increase in the dissoci-
ation rate (Table 1). A steeper slope in the dissociation curve
of the sensograms is apparent in these mutants (Fig. 4).Fig. 4. SPR sensograms ofmutations in p13 that affected binding to huIL-18 ormuIL
andmurine IL-18 by SPR. Eachmutant was captured at constant levels, and IL-18wa
was subtracted from each curve. (A, C, E, G, and I) Binding sensograms of mutant
interaction with huIL-18. (A, B) Wild-type p13. (C, D) F49A. (E, F) E69A. (G, H) E
superimposed in black. Below each binding sensograms, a residual plot is shown t
BIAevaluation software. Each set of curves is representative of at least three experThese three mutations affected binding to both species, but
to different extents. F49A has the same affinity for both
ligands, but as a result of a 9-fold increase in kd with huIL-
18 and an almost 140-fold increase in kd with muIL-18. The
ka of F49A is not different from wild type, although the
binding curve is visually different (Fig. 4C). The binding
portion of the curve is the result of a combination of the ka
and kd, and the very high kd causes this mutant to rapidly
reach equilibrium during injection. The affinity of E77A for
both species dropped proportionately, however, inspection
of the sensograms reveals that the mutation has a more
significant effect on binding huIL-18. Consistently low
binding levels were detected with huIL-18. Analysis of
the detectable binding demonstrates an increase in the
dissociation rate, but in addition the low binding level
suggests that only a fraction of the captured population is
capable of binding. This was not the case with muIL-18,
which had binding levels comparable to wild-type protein.
Low binding levels were also observed with E69A. Because
the affinity of E69A is dramatically lower, and the same
concentration series was used for all mutants, lower binding
levels are expected.-18. Point mutationswere introduced into p13 and tested for binding to human
s injected at varying concentrations, including a blank injection (0 nM)which
interaction with muIL-18. (B, D, F, H, and J) Binding sensograms of mutant
77A. (I, J) H70A. Experimental data are shown in color, and fitted curves are
o demonstrate goodness of fit. Data were fitted to a 1:1 binding model using
iments.
Table 1
Summary of kinetics and affinity measurements for mutants that affected binding to muIL-18 or huIL-18a
Name Murine IL-18 Human IL-18
KD (nM) ka (105) (M1 s1) kd (104) (s1) KD (nM) ka (105) (M1 s1) kd (104) (s1)
p13 0.16 F 0.05 9.54 F 2.54 1.42 F 0.21 5.14 F 1.41 0.53 F 0.02 2.43 F 0.34
F49A 22.20 F 3.59 5.77 F 0.86 125.00 F 21.80 42.10 F 13.60 0.33 F 0.09 13.6 F 0.70
E69A 4.33 F 0.32 13.60 F 6.90 45.30 F 5.61 1290.00 F 801.00 0.06 F 0.02 72.70 F 18.60
H70A 0.15 F 0.04 14.00 F 2.30 2.01 F 0.30 50.60 F 30.50 0.66 F 0.38 26.10 F 1.90
E77A 1.39 F 0.41 7.33 F 2.70 9.30 F 0.55 47.90 F 12.40 0.33 F 0.11 14.80 F 1.99
a Mutants expressed as Fc-fusion proteins were captured on a BIAcore sensor chip and binding measured using varying concentrations of IL-18. Each mutant
was tested at least three times. Data were analyzed by fitting to a 1:1 binding model using BIAevaluation software. No significant binding was found with Fc
alone.
D.J. Esteban, R.M.L. Buller / Virology 323 (2004) 197–207202H70A was unique among the mutants tested in that there
was no change in binding to muIL-18, but a 10-fold
reduction in affinity for huIL-18 (Table 1). Thus, H70 is
specifically involved in binding huIL-18.
The kinetics and affinity of Y51A, K60A, D62A, E63A,
K66A, and R82A for both human and muIL-18 were not
different from wild type (Fig. 5). L71A showed a very
modest increase in dissociation rate for huIL-18 but this is
not likely sufficiently different to be biologically significant.
Mutants Y53A, D58A, F67A, and K93A did not have
significant binding affinity (Fig. 6). When the same amount
of protein was captured, wild-type protein bound more than
60 RU of muIL-18, although Y53A, D58A, F67A, and
K93A demonstrated only background levels consistent with
nonspecific interaction. These mutations also demonstrated
no binding to huIL-18. Mutant L55A demonstrated wild-
type kinetics (Fig. 5); however, it appeared to be structurally
unstable. Low binding levels were observed, indicating low
specific activity, and during a kinetics experiment, capture
levels steadily decreased with each cycle. This suggests that
the protein may have precipitated during the experiment,
effectively decreasing the concentration over time, become
aggregated, or misfolded so as to interfere with capture.Fig. 6. Mutations in p13 that eliminated binding activity. Wild type and
mutant p13 were captured to equivalent levels using antihuman IgG
antibody on the surface of a BIAcore sensor chip. muIL-18 (30 nM) was
injected for 3 min, followed by 10 min dissociation, and binding was
measured as a change in response (RU).Sequencing demonstrated that no additional mutations were
present. Furthermore, when heated to 56 jC, L55A could no
longer be captured, although heating had no effect on
capture or IL-18 binding by wild type or the mutants that
demonstrated an increased dissociation rate (data not
shown). Binding curves were analyzed using locally fitted
theoretical Rmax to compensate for changing capture levels
and binding was found to be consistent with wild-type
kinetics; however, the behavior of this protein in solution
was clearly abnormal.Discussion
IL-18BPs are a family of proteins found only in mam-
mals and poxviruses. Poxviruses encode a large number of
immune evasion proteins, which most likely were adopted
from the host during viral evolution. The study of viral
immune modulators can provide insight not only into
mechanisms of immune evasion, but also into normal
immune function and regulation. Mammalian IL-18BPs
play a role in regulating the immune system and operates
under a feedback mechanism to control IL-18 activity (Muhl
et al., 2000; Paulukat et al., 2001). Inappropriate or unreg-
ulated IL-18 activity can result in, or contribute to, the
damaging autoimmune response in diseases such as Crohn’s
disease (Kanai et al., 2001; Pizarro et al., 1999) and
rheumatoid arthritis (Gracie et al., 1999); thus, the potential
use of IL-18BPs in treatment of autoimmunity is obvious.
Understanding the structure of the IL-18BP family as a
whole is therefore important for defining the molecular
characteristics that allow the binding proteins to effectively
block interaction with the receptor.
Modeling of huIL-18BP and MC54L identified residues
that may be important in interaction with IL-18 and muta-
genesis studies subsequently supported some of the predic-
tions (Kim et al., 2000; Xiang and Moss, 2001a, 2001b).
Mutagenesis of MC54L demonstrated that the corresponding
residues were required for binding, indicating that the viral
and human protein have conserved functional epitopes
(Xiang and Moss, 2001a). Orthopoxvirus IL-18BP homo-
logs have also been shown to bind IL-18 (Born et al., 2000;
Calderara et al., 2001; Smith et al., 2000), however, with
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this study, we extend the analysis of IL-18 binding to a
mouse orthopoxvirus IL-18 binding protein, and compare
the binding requirements for human and mouse IL-18.
Most mutations that altered binding affected both human
and murine IL-18, although species-specific differences
were noted. F49A, E69A, and E77A all altered binding to
both ligands, but not to the same extent. Mutation of F49
increased the dissociation rate with muIL-18 approximately
140-fold, although the effect on binding huIL-18 was 9-fold,
indicating that F49 plays a more significant role in muIL-18
binding. The F49A mutant has comparable affinity for huIL-
18 and muIL-18, but with strikingly different kinetics. F49A
maintains the higher association rate with muIL-18 that is
seen with wild-type p13, thus the equalization of affinity for
the two ligands is due to a more significant increase in the
dissociation rate with muIL-18. Interestingly, in MC54L, the
wild-type residue at position 63 (corresponding to F49 in
p13) is actually Val, and a Val to Ala mutation had little
effect (Xiang and Moss, 2001a). However, mutation of V63
to Phe, the residue conserved in all other members of the IL-
18BP family, increased the affinity for huIL-18 dramatically
underscoring the important role of Phe in binding. Although
mutation of the corresponding residue in huIL-18BP also
increased the dissociation rate, no species-specific differ-
ence was detected (Xiang and Moss, 2001b).
Mutation of E77 increased the dissociation rate with both
ligands but also specifically reduced the binding level with
huIL-18. The reduced binding level indicates that only a
fraction of the population of proteins captured by the
immobilized antibody on the BIAcore chip surface is
capable of binding huIL-18. Those capable of binding do
so with a change in dissociation rate proportional to the
change seen with muIL-18. This may indicate that two
populations of proteins are present; one population that
binds human IL-18 with reduced affinity, and another that
lacks binding activity. However, these two populations do
not differ in their binding to muIL-18.
H70 is unique among residues tested in that it is
involved in binding human but not murine IL-18. H70 is
conserved in the orthopoxvirus IL-18BPs, all isoforms of
muIL18BP and all functional and one nonfunctional iso-
form of huIL-18BP (Kim et al., 2000). In MC54L, it is
conserved in MCV type 4 and replaced with another highly
polar residue, Glu, in MCV types 1 and 2 (Xiang and Moss,
2001a). Mutation of the corresponding residue in huIL-
18BP, H107, had no effect on binding muIL-18 but a 3-fold
increase in dissociation rate with huIL-18 (Xiang and Moss,
2001a). This residue is more important in binding huIL-18
by p13 because H70A had a 10-fold higher dissociation
rate. Alignment of p13 with the IL-1R crystal structure
reveals that many of the residues that contribute to binding
are located along h-strands c and d, which are joined by a
h-turn that is shortened in MC54L and huIL-18BP (Fig. 1).
It is possible that the longer h-turn of p13 and the
orthopoxvirus IL-18BPs results in a change in side chainorientation and places H70 in a position that improves its
interaction with huIL-18. Residues in the h-turn conserved
between p13 and IL-1R are not directly involved in IL-18
binding.
The affinity of the orthopoxvirus IL-18BPs thus far
tested (ECTV p13, CPXV C8L, VARV D7L) have a 10-
fold higher association rate with muIL-18 than huIL-18
(Calderara et al., 2001). This study did not identify inter-
actions responsible for this difference. It is possible that this
property is conferred by differences between human and
muIL-18, rather than the binding proteins. Indeed, binding
to muIL-18 with higher affinity than huIL-18 appears to be a
common property of all IL-18BPs including the huIL-18BP
and those from human pathogens, suggesting that there may
an intrinsic property of muIL-18 that permits higher affinity
interaction. Mutagenesis studies of human and muIL-18
may be necessary to address this possibility.
Residues Y53, D58, F67, and K93 were found to be
absolutely required for binding to IL-18. Mutation of
residues corresponding to Y53 and F67 in MC54L also
ablated binding, and in huIL-18BP results in a dramatic
reduction of affinity due to a large increase in the disso-
ciation rate. It is likely that these residues are critical for
interaction with IL-18, rather than elimination of binding
affinity being the result of structural rearrangements. Ala-
nine scanning mutagenesis has been used successfully to
analyze many proteins (Thorn and Bogan, 2001), and Ala
is not a h-sheet or a-helix breaker and does not introduce
steric or electrostatic constraints; thus, it is unlikely to
induce major structural changes. All mutant proteins ex-
cept the cysteine mutants were expressed and secreted at
levels comparable to wild type. Because poor expression
and secretion is associated with misfolded or unstable
proteins, this suggests that gross structural abnormalities
are unlikely.
Molecular modeling of huIL-18BP (Kim et al., 2000)
proposed that binding was the result of burial of large
hydrophobic patches (involving residues corresponding to
F49, Y51, Y53, T113, and L115 in p13) and electrostatic
interactions (involving residues corresponding to K93 and
E77 in p13). The three mutagenesis studies have supported
the role of the hydrophobic residues Y53 and F49, and
downplay the significance of Y51. Residues corresponding
to T113 and L115 have only been mutated in huIL-18BP
and showed no effect. Both electrostatic interactions were
confirmed to be important in p13. Mutation of E77 resulted
in a significant increase in the dissociation rate, and K93A
demonstrated no binding to IL-18. This differs from huIL-
18BP, in which mutation of the equivalent K130 to Ala did
not affect affinity; however, changing the charge by mutat-
ing to Glu resulted in no detectable binding.
Individual mutations of all four cysteines resulted in
apparent structural abnormalities that prevented normal
secretion and binding affinity. The IL-18BPs can be
classified as members of the Ig superfamily of proteins,
having the characteristic h-sandwich stabilized by a disul-
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was expected to introduce structural abnormalities. It is
likely that the disulfide bond stabilizing the h-sheet
involves C110 and either C39 or C42. However, a second
disulfide bond may be present because all four cysteines
appear to be important for proper folding. This second
disulfide bond may allow proper folding of the N-terminus
of the protein.
Mammalian and viral IL-18BPs are highly homologous
to each other but differ significantly in sequence from the
IL-18 receptor. IL-18 is a member of the IL-1 family of
cytokines (Bazan et al., 1996; Kato et al., 2003), and both
the a- and h-receptor chains are related to the IL-1 receptor
(Born et al., 1998; Torigoe et al., 1997). Alone, the a-chain
forms the low affinity receptor, although the h-chain
confers higher affinity interaction and is required for cell
signaling. The solution structure of huIL-18 has recently
been solved, and extensive mutagenesis identified two sites
that interact with IL-18Ra (Kato et al., 2003). The IL-
18BPs may interact with site II of IL-18, which contacts
domain I of IL-18Ra. Mutation of residues E6 and K53 of
IL-18 were previously shown to alter its biological activity,
and these mutants were not neutralized by IL-18BP (Kim et
al., 2001; Larsen et al., 1990). These residues may not be
directly involved in receptor interaction, but are near site II
(Kato et al., 2003). Thus, it is likely that this region is
bound by IL-18BPs, blocking interaction with IL-18Ra. It
remains to be determined if IL-18Ra and the IL-18BPs
have the same contact points or if their binding regions
simply overlap.
Biacore provides a highly flexible platform in which to
measure protein–protein interactions. In this study, we used
an antibody capture system, in which immobilized antihu-
man IgG is used to capture Fc-fusion proteins. Capture
systems offer the optimal conditions for kinetic analysis by
allowing easily controlled levels of captured protein and
consistent orientation resulting in a homogeneous popula-
tion of interacting molecules. In contrast, direct immobili-
zation Methods, in which one of the interacting proteins is
covalently linked to the Biacore chip, usually via primary
amines, frequently results in partial inactivation of the
population of proteins and may alter binding properties if
amines are involved in the protein–protein interaction being
measured. The difference in binding affinities reported in
Calderara et al. (2001) and Xiang and Moss (1999a, 1999b)
compared to Xiang and Moss (2001a, 2001b) are likely
explained by the difference in Methods; the former using
direct immobilization, and the latter using a streptavidin–
biotin capture system. The results in this study also differ
from those using direct immobilization (Calderara et al.,
2001), which also may be attributable to the difference in
the Methods. In addition, differences in the source and
activity of the IL-18, used as the analyte, may also contrib-
ute to some differences. Nonetheless, although differences
exist in the absolute values determined using these different
Methods, the trends are consistent.Materials and Methods
Cell culture
CV-1/EBNA-1 cells were maintained in DMEM (Bio-
whittaker, Walkersville, MA) containing 10% FCS
(HyClone, Gibco, Carlsbad, CA) and supplemented with
L-glutamine and penicillin/streptomycin.
MuIL-18 and huIL-18
Murine IL-18 (Biosource International, Camarillio, CA)
was stored lyophilized until immediately before use in
surface plasmon resonance (SPR) experiments. Following
reconstitution, it was stored at 4 jC with no apparent change
in activity over the period of storage. Human IL-18 was
expressed in E. coli and purified according to previously
published Methods (Liu et al., 2000) with some modifica-
tions. The bacteria were lysed, clarified by centrifugation,
and the supernatant was mixed with a 50% slurry of
glutathione agarose beads (Amersham Pharmacia, Piscat-
away, NJ) at 4 jC for at least 3 h. The beads were washed
and resuspended in twice the bed volume in cold PBS.
Factor Xa (New England Biolabs, Beverly, MA) was added
at a concentration of 1 Ag/ml of lysate and incubated at 23
jC for 4 h. The cleaved product in the supernatant was
harvested by centrifugation. The supernatant was assessed
for purity and concentration by SDS-PAGE and silver
staining, and was found to be greater than 90% pure.
HuIL-18 was stored at 70 jC and thawed immediately
before use. HuIL-18 produced in this manner was tested in a
bioassay as previously described (Konishi et al., 1997) and
found to be biologically active.
Mutagenesis
Mutations in p13 were introduced by site-directed
mutagenesis (Genetailor Mutagenesis Kit, Invitrogen,
Carlsbad, CA). The expression vector pDC409-p13Fc, to
express p13 as a human IgG1 Fc-fusion, was a generous
gift of Amgen. The source of the p13 gene was ECTV-
Moscow. Wild-type pDC409p13-Fc was methylated using
DNA methylase and used as template for mutagenic PCR.
Primers were designed to prime in opposite directions,
with a 15–20 nucleotide overlap for efficient circulariza-
tion of the product. Cycling conditions using High-Fidelity
Platinum Taq Polymerase (Invitrogen) were as follows: 94
jC for 4 min, 20 cycles of 1 min at 94 jC, 1 min at 55
jC, and 8 min at 68 jC, and a final extension of 10 min
at 68 jC. The PCR product was used to transform DH5a
E. coli cells, and plated on LB plates with ampicillin.
Plasmid DNA was extracted from overnight cultures of
transformant colonies (QIAprep Minipreps, Qiagen, Valen-
cia, CA) and screened by DNA sequencing of both
strands. Mutagenesis efficiency was found to be greater
than 90%.
r / Virology 323 (2004) 197–207 205Expression and purification
Expression from pDC409 is driven by the HIV LTR
under the control of HIV Tat (Dower et al., 1989; McMahan
et al., 1991). HIV Tat is expressed from the plasmid, driven
by the SV40 early promoter. The plasmid also contains the
Epstein–Barr Virus (EBV) origin of replication. The cell
line CV-1/EBNA-1 constitutively expresses the EBV repli-
cation protein EBNA-1 and following transfection the
plasmid is maintained as a low-copy-number episome.
Expression was achieved by transfection of T-150s of CV-
1/EBNA-1 cells using DEAE-dextran. Briefly, DNA was
mixed with DMEM-10 containing 125 AM chloroquine,
then DEAE-dextran was added. The DNA mixture was
added to cells in DMEM-10 with chloroquine and incubated
4.5 h. The media was removed, and cells were incubated in
DMEM containing 10% DMSO for 5 min at room temper-
ature, then replaced with DMEM-10. Culture media was
collected weekly to harvest secreted protein. Media from
transfected cells was collected and purified by FPLC using a
HiTrap protein-G column (AKTA, Amersham Biosciences,
Piscataway, NJ). Briefly, culture supernatants were loaded
onto the column, which was then washed with PBS, pH 7.4.
Bound protein was eluted in 50 mM citrate, pH 3, and
fractions were collected and neutralized with 1.4 M HEPES,
pH 11. Peak fractions were pooled and dialyzed against
PBS. Purification was assessed by silver staining (BioRad,
Hercules, CA) and identity of the purified protein was
verified by Western blot using polyclonal rabbit anti-p13
antiserum.
Surface plasmon resonance
Interaction of the binding proteins with IL-18 was
measured by surface plasmon resonance (BIAcore 2000,
Biacore Inc., Piscataway, NJ). All flow cells (FC) of a CM5
sensor chip were activated with 1-ethyl-3(3-dimethylamino-
propyl)-carbodiimide hydrochloride (EDC)/N-hydroxysuc-
cinimide (NHS), for 6 min at 5 Al/min. Antihuman IgG
(Jackson Immunoresearch, Pennsylvania) was immobilized
on all FC, using a flow rate of 5 Al/min, for 7 min. The
surface was blocked by injecting ethanolamine for 7 min at
5 Al/min. For kinetic studies, Fc-fusion proteins were
captured in FC2, FC3, or FC4 using FC1 as a reference
cell, followed by an injection of varying concentrations of
IL-18 over all surfaces. Typically, only 150–200 RU of
binding protein was captured to keep the Rmax low. Cycle
conditions were as follows: 3 min capture at 5 Al/min, 3 min
analyte injection at 30 Al/min over all FC, followed by 12
min dissociation time. The surface was regenerated with a
1-min injection of 5 mM HCl, pH 1.5. At least one of the
dilutions was run in duplicate in each experiment, and IL-
18 concentrations were injected in random order to elim-
inate possible error introduced by sequential injection.
Concentrations of huIL-18 were 277.78, 92.6, 30.9, 10.3,
3.4, and 0.38 nM, and concentrations of muIL-18 were 30,
D.J. Esteban, R.M.L. Bulle10, 3.3, 1.11, 0.37, and 0.04 nM. To rule out the possibility
of leaching between flow cells during injection and disso-
ciations phases, experiments were repeated with protein
captured on different flow cells, or individually, using only
FC1 and FC2. Each mutant was tested at least once on FC2.
No flow-cell-dependent effect was detected. Bulk shift and
noise introduced by BIAcore hardware was removed by
subtraction of the signal in FC1 from all other FC. A blank
buffer injection was subtracted from binding curves before
analysis in BIAevaluation 3.2 software. All experiments
were performed at 25 jC.
Western blot and silver staining
Expression and purification was assessed by 12% SDS-
PAGE followed by Western blot or silver staining. For
Western blots, gels were transferred to PVDF membrane,
blocked in 5% nonfat dry milk in PBS, and then incubated
with rabbit anti-p13 antiserum or HRP-conjugated goat
antihuman IgG1 (Sigma, St. Louis, MO). For anti-p13
blots, HRP-conjugated anti-rabbit IgG (KPL, Gaithersburg,
MA) was used as a secondary antibody. Bands were
detected using ECL Plus (Amersham Biosciences) and
exposed to film or captured by digital imaging (Alpha
Innotech, San Leandro, CA). For silver stains, gels were
fixed and developed according to manufacturer’s instruc-
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